We studied impact of ethylmethylhydroxypyridine succinate n the course of chronic heart failure during 3 years follow-up after myocardial infarction. Dynamics of objective and subjective parameters was assessed in 100 patients; 48 patients received conventional therapy (control group) and 52 patients received conventional therapy plus ethylmethylhydroxypyridine succinate (main group). Addition of ethylmethylhydroxypyridine succinate resulted in decreases of rates of complications, mortality, and re-hospitalizations. Increases of myocardial contractile function, myocardial adaptation, as well as improvement of range of biochemical parameters were also observed. The latter changes were indicative of antioxidant, anti-inflammatory, anti-stress activities of Ethylmethylhydroxypyridine succinate. Moreover, antidepressant and antineurotic effects of complex therapy including ethylmethylhydroxypyridine succinate was confirmed.
Heart Failure/drug therapy , Myocardial Contraction/drug effects , Oxidative Stress/drug effects , Pyridines , Ventricular Dysfunction, Left/drug therapy , Antioxidants/administration & dosage , Antioxidants/adverse effects , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/adverse effects , Depression/drug therapy , Depression/etiology , Echocardiography , Female , Health Status Indicators , Heart Failure/etiology , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Male , Middle Aged , Mortality , Myocardial Infarction/complications , Myocardial Infarction/physiopathology , Patient Readmission , Pyridines/administration & dosage , Pyridines/adverse effects , Severity of Illness Index , Treatment Outcome , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/physiopathology
